A deterministic snapshot of the global clinical-trial landscape — every figure reproducible from the ClinicaLister knowledge graph.
Registered in the past 7 days.
Trials that moved to a new overall status.
Terminations, withdrawals and suspensions — with the sponsor's stated reason.
Study did not receive funding and was never carried out.
Study terminated early due to COVID-19. Interim data analyses in progress.
\<75% participation
Terminated in IRB
The study was withdrawn prior to initiation. The protocol was submitted for IRB review but was not approved. No participants were enrolled.
Study was withdrawn prior to enrollment following non-approval by IRB.
PI Request
Lack of enrollment
Study closed before the planned recruitment target was reached because the study period ended before full recruitment could be completed. Recruitment ceased at study closure and data collection was completed for enrolled participants.
Lack of financial support
Documents have been pending from the coordinator since July 16, 2019. No response despite multiple follow-ups.
50 approvals month-to-date.
| Sponsor | Drug | Approved |
|---|---|---|
| AUROBINDO PHARMA LTD | ADAPALENE; BENZOYL PEROXIDE | 2026-07-22 |
| TEVA PHARMS USA | CANAGLIFLOZIN | 2026-07-21 |
| AUROBINDO PHARMA LTD | BUPROPION HYDROCHLORIDE | 2026-07-21 |
| TEVA PHARMS INC | TOLVAPTAN | 2026-07-21 |
| ZYDUS PHARMS | FLUVOXAMINE MALEATE | 2026-07-21 |
| NOVITIUM PHARMA | PITOLISANT HYDROCHLORIDE | 2026-07-21 |
| AFT PHARMACEUTICALS LTD | SIROLIMUS | 2026-07-20 |
| MSN | CARFILZOMIB | 2026-07-20 |
7.7% of the last year's EMA authorisations were conditional.
| Medicine | Authorised |
|---|---|
| Etcamah | 2026-07-20 |
13 new · 0 resolved · 106 currently active.
| Newly reported shortage | Posted |
|---|---|
| Lopinavir and Ritonavir Oral Solution | 2026-07-24 |
| Lopinavir and Ritonavir Tablet | 2026-07-24 |
| Ritonavir Oral Powder | 2026-07-24 |
| Ritonavir Tablet | 2026-07-24 |
| Aspirin Suppository | 2026-07-23 |
| Belladonna and Opium Suppository | 2026-07-23 |
| Bendamustine Hydrochloride Injection, Solution | 2026-07-23 |
| Hydrocortisone Acetate Suppository | 2026-07-23 |
| Hydromorphone Hydrochloride Suppository | 2026-07-23 |
| Morphine Sulfate Suppository | 2026-07-23 |
| Podophyllum Resin Topical Tincture | 2026-07-23 |
| Succinylcholine Chloride Injection | 2026-07-23 |
| Dextrose Monohydrate 5% Injection | 2026-07-20 |
Most new trials this week.
Industry sponsors, new trials · trailing 28 days.
New links where the molecule is the studied intervention.
FDA device clearance data is current; MAUDE adverse-event and recall feeds lag ~1-2 months.
Whole-corpus totals and rankings, recomputed every week.
Monthly new registrations across ClinicalTrials.gov. Puts the weekly count in context.
By linked trials (MONDO rollup).
Among the 67,934 trials with a mapped site location — not the whole corpus.
| Sponsor | Trials |
|---|---|
| Cairo University | 4,754 |
| Assiut University | 4,714 |
| GlaxoSmithKline | 3,620 |
| National Cancer Institute (NCI) | 3,551 |
| Assistance Publique - Hôpitaux de Paris | 3,523 |
| AstraZeneca | 3,464 |
| Pfizer | 3,287 |
| Mayo Clinic | 3,221 |
| M.D. Anderson Cancer Center | 3,012 |
| Novartis Pharmaceuticals | 2,676 |
| National Taiwan University Hospital | 2,580 |
| Massachusetts General Hospital | 2,551 |
| National Institute of Allergy and Infectious Diseases (NIAID) | 2,436 |
| Boehringer Ingelheim | 2,282 |
| University of California, San Francisco | 2,145 |
| Stanford University | 2,138 |
| Merck Sharp & Dohme LLC | 2,135 |
| Riphah International University | 2,112 |
| Hoffmann-La Roche | 2,079 |
| Eli Lilly and Company | 2,070 |
| Duke University | 2,044 |
| Memorial Sloan Kettering Cancer Center | 1,941 |
| Seoul National University Hospital | 1,881 |
| Ain Shams University | 1,858 |
| Hospices Civils de Lyon | 1,833 |
| Condition | Trials |
|---|---|
| breast cancer | 11,774 |
| obesity disorder | 9,520 |
| type 2 diabetes mellitus | 9,120 |
| chronic pain syndrome | 8,786 |
| cancer | 8,215 |
| HIV infectious disease | 8,196 |
| COVID-19 | 7,640 |
| non-small cell lung carcinoma | 6,358 |
| diabetes mellitus | 6,117 |
| hypertensive disorder | 6,114 |
| colorectal cancer | 5,998 |
| cerebrovascular disorder | 5,988 |
| coronary artery disorder | 5,929 |
| prostate cancer | 5,831 |
| depressive disorder | 5,821 |
| cardiovascular disorder | 5,592 |
| heart failure | 4,885 |
| anxiety disorder | 4,874 |
| injury | 4,473 |
| Parkinson disease | 4,424 |
| asthma | 4,199 |
| cognitive disorder | 4,159 |
| lung cancer | 4,056 |
| benign essential hypertension | 3,869 |
| neuralgia | 3,823 |
| Molecule | Trials |
|---|---|
| carboplatin | 7,140 |
| paclitaxel | 5,476 |
| isoniazid | 5,310 |
| prednisolone | 5,233 |
| cyclophosphamide | 5,105 |
| ropivacaine | 4,831 |
| dexamethasone | 4,778 |
| bevacizumab | 4,576 |
| cisplatin | 4,451 |
| lidocaine | 3,588 |
| aspirin | 3,350 |
| gemcitabine | 3,170 |
| bupivacaine | 3,098 |
| desoxycorticosterone acetate | 2,982 |
| pembrolizumab | 2,969 |
| metformin | 2,955 |
| sitagliptin and metformin hydrochloride | 2,955 |
| rituximab | 2,924 |
| meprednisone | 2,850 |
| dapagliflozin metformin hydrochloride | 2,788 |
| sitagliptin metformin hydrochloride | 2,765 |
| docetaxel | 2,755 |
| linagliptin and metformin hydrochloride | 2,752 |
| fluorouracil | 2,698 |
| alogliptin and metformin hydrochloride | 2,694 |
Standing competitive & regulatory landscape — who is developing what, at which stage, and which drugs are about to lose exclusivity.
Active trials by the most prolific industry sponsors, split by phase.
| Phase 1 | Phase 2 | Phase 3 | |
|---|---|---|---|
| GlaxoSmithKline | 1,091 | 861 | 890 |
| AstraZeneca | 1,018 | 551 | 801 |
| Pfizer | 1,173 | 709 | 652 |
| Novartis Pharmaceuticals | 508 | 834 | 734 |
| Boehringer Ingelheim | 1,065 | 322 | 399 |
| Merck Sharp & Dohme LLC | 697 | 550 | 738 |
| Hoffmann-La Roche | 491 | 480 | 568 |
| Eli Lilly and Company | 825 | 535 | 548 |
FDA drugs whose exclusivity expires soon (distinct substances).
| Drug (losing exclusivity < 6mo) | Expires |
|---|---|
| Alogliptin Benzoate; Metformin Hydrochloride | 2026-07-27 |
| Alogliptin Benzoate | 2026-07-27 |
| Octreotide Acetate | 2026-08-02 |
| Pexidartinib Hydrochloride | 2026-08-02 |
| Fedratinib Hydrochloride | 2026-08-16 |
| Valbenazine Tosylate | 2026-08-18 |
| Gallium Ga-68 Edotreotide | 2026-08-21 |
| Cobicistat | 2026-08-22 |
| Difelikefalin Acetate | 2026-08-23 |
| Sofosbuvir | 2026-08-28 |
| Ledipasvir; Sofosbuvir | 2026-08-28 |
| Citalopram Hydrobromide | 2026-09-16 |
| Phentolamine Mesylate | 2026-09-25 |
| Atogepant | 2026-09-28 |
| Miglustat | 2026-09-28 |
FDA drugs carrying each designation.
Molecules most often used as the comparator arm (the standard to beat).
Every figure is a deterministic SQL aggregate over the ClinicaLister knowledge graph as of the report date. No figure is AI-generated or estimated; each is reproducible and traceable to its public source.
Sources: ClinicalTrials.gov · EU CTIS · openFDA (drugs, devices, shortages) · EMA · MONDO disease ontology · GSRS · GUDID · Europe PMC / PubMed
Every figure above is a deterministic aggregate over the ClinicaLister knowledge graph — and one click deep in the product, with a source behind each claim.
Machine-readable: download this edition as JSON above, or query the full archive programmatically via the public get_public_report_snapshots endpoint.